| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| ci-1033 | rac-alpha serine/threonine-protein kinase | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] |
0.12 | phase 2 | unknown |
| ci-1033 | epidermal growth factor receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] |
0.36 | phase 2 | unknown |
| ci-1033 | erbb2 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] |
0.31 | phase 2 | unknown |
| ci-1033 | erbb4 tyrosine kinase receptor | NA | Successful target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] |
NA | phase 2 | unknown |
| click here to return to the previous page | ||||||||